ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $33 | $16 | $8 | $87 |
| % Growth | 106.8% | 97.1% | -90.8% | – |
| Cost of Goods Sold | $8 | $5 | $4 | $4 |
| Gross Profit | $24 | $11 | $4 | $83 |
| % Margin | 74.8% | 68.3% | 49.3% | 95.5% |
| R&D Expenses | $3 | $4 | $3 | $3 |
| G&A Expenses | $0 | $54 | $0 | $0 |
| SG&A Expenses | $75 | $54 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $38 | $32 |
| Operating Expenses | $78 | $58 | $41 | $35 |
| Operating Income | -$53 | -$48 | -$37 | $47 |
| % Margin | -163.7% | -302.9% | -466.3% | 54.5% |
| Other Income/Exp. Net | $2 | $3 | $3 | $3 |
| Pre-Tax Income | -$51 | -$45 | -$34 | $50 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$45 | -$34 | $50 |
| % Margin | -157.4% | -285.6% | -425.7% | 57.7% |
| EPS | -0.52 | -0.46 | -0.35 | 0.51 |
| % Growth | -13% | -31.4% | -168.6% | – |
| EPS Diluted | -0.52 | -0.46 | -0.35 | 0.51 |
| Weighted Avg Shares Out | 99 | 98 | 98 | 98 |
| Weighted Avg Shares Out Dil | 99 | 98 | 98 | 98 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $0 | $0 | $0 |
| EBITDA | -$49 | -$45 | -$37 | $47 |
| % Margin | -150.1% | -283.8% | -462.8% | 54.5% |